CC
Casdin Capital Portfolio holdings
AUM
$1.1B
1-Year Return
24.98%
This Quarter Return
+15.19%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.5B
AUM Growth
+$190M
(+15%)
Cap. Flow
+$50.8M
Cap. Flow
% of AUM
3.39%
Top 10 Holdings %
Top 10 Hldgs %
78.34%
Holding
38
New
–
Increased
10
Reduced
7
Closed
3
Top Buys
| 1 |
Illumina
ILMN
|
$35.2M |
| 2 |
Codexis
CDXS
|
$18.8M |
| 3 |
Standard BioTools
LAB
|
$14.1M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$6.26M |
| 5 |
Guardant Health
GH
|
$5.74M |
Top Sells
| 1 |
Revolution Medicines
RVMD
|
$13.3M |
| 2 |
Pliant Therapeutics
PLRX
|
$10.8M |
| 3 |
Denali Therapeutics
DNLI
|
$9.03M |
| 4 |
Veracyte
VCYT
|
$6.52M |
| 5 |
Kyverna Therapeutics
KYTX
|
$4.31M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTNM
26
Contineum Therapeutics
CTNM
$322M
| $5.68M | 0.38% |
296,666
| – | – |
|
27
Century Therapeutics
IPSC
$43.6M
| $5.49M | 0.37% |
3,212,316
-1,978,190
| -38% | -$3.38M |
|
|
GRAL
28
GRAIL, Inc. Common Stock
GRAL
$1.33B
| $4.82M | 0.32% |
350,000
+270,001
| +338% | +$3.72M |
|
29
Absci
ABSI
$368M
| $3.72M | 0.25% |
973,260
| – | – |
|
30
Pacific Biosciences
PACB
$381M
| $1.76M | 0.12% |
1,035,859
| – | – |
|
31
Prime Medicine
PRME
$663M
| $1.42M | 0.09% |
367,175
| – | – |
|
|
EXAI
32
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $1.04M | 0.07% |
213,900
| – | – |
|
33
Monte Rosa Therapeutics
GLUE
$305M
| $456K | 0.03% |
86,014
-175,000
| -67% | -$928K |
|
34
Ginkgo Bioworks
DNA
$660M
| $297K | 0.02% |
36,493
-1
| -0% | -$8 |
|
|
KRON
35
DELISTED
Kronos Bio
KRON
| $124K | 0.01% |
123,839
| – | – |
|
|
36
Pliant Therapeutics
PLRX
$114M
| – | – |
-1,000,000
| Closed | -$10.8M |
|
|
37
Kyverna Therapeutics
KYTX
$170M
| – | – |
-575,000
| Closed | -$4.31M |
|
|
OMIC
38
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| – | – |
-44,129
| Closed | -$373K |
|